Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Leflunomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH known ✓ | Q02127 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | CCKBR | P32239 | 1/20 | 1.00 |
| ▸ | MC4R | P32245 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leflunomide SCHEMBL1243495 | 1.00 | RAB9A (1.00) | RAB9ADHODHNPC1SMN1; SMN2GMNN | |
| Leflunomide SCHEMBL29271960 | 0.96 | RAB9A (0.92) | RAB9ADHODHNPC1SMN1; SMN2GMNN | |
| SCHEMBL11428900 | 0.94 | RAB9A (0.88) | RAB9ADHODHNPC1SMN1; SMN2GMNN | |
| SCHEMBL8812525 | 0.93 | RAB9A (0.86) | RAB9ADHODHNPC1SMN1; SMN2GMNN | |
| Leflunomide SCHEMBL18584841 | 0.92 | RAB9A (0.84) | RAB9ADHODHNPC1SMN1; SMN2GMNN | |
| SCHEMBL12356679 | 0.90 | DHODH (0.82) | RAB9ADHODHNPC1SMN1; SMN2GMNN | |
| SCHEMBL26075462 | 0.89 | DHODH (0.81) | RAB9ADHODHNPC1SMN1; SMN2GMNN | |
| SCHEMBL9812368 | 0.87 | RAB9A (0.78) | RAB9ADHODHNPC1SMN1; SMN2GMNN | |
| SCHEMBL7459817 | 0.86 | DHODH (0.76) | RAB9ADHODHNPC1SMN1; SMN2GMNN | |
| SCHEMBL1826746 | 0.85 | RAB9A (0.73) | RAB9ADHODHNPC1SMN1; SMN2GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 56572 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260140113-A1 | PROTEIN BIOMARKERS FOR USE IN LUPUS NEPHRITIS | EXAGEN INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260130991-A1 | HUMANIZED ANTI-CD40 ANTIBODIES AND USES THEREOF | PRIMATOPE THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | claimed |
| US-20260132191-A1 | METHODS FOR MODULATING ACTIVITY OF IL-18 FOR TREATMENT OF CD4+ T CELL MEDIATED AUTOIMMUNITY AND IMMUNOPATHOLOGY | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-05-14 | — | — | US | claimed |
| US-20260130998-A1 | TREATMENT OF AUTOIMMUNE DISORDERS USING CHIMERIC ANTIGEN RECEPTOR THERAPY | NOVARTIS AG (CH) | 2026-05-14 | — | — | US | claimed |
| CN-122028914-A | Combination therapy for autoimmune disorders | 拜奥海芬治疗学有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122012706-A | Application of DHODH-CHK alpha-TRIM 28 in screening medicines for inhibiting proliferation or growth of colorectal cancer cells | 山西医科大学 | 2026-05-12 | — | — | CN | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4735116-A2 | ANTI-TRAILR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| WO-1996001111-A1 | USE OF LEFLUNOMIDE TO CONTROL AND REVERSE CHRONIC ALLOGRAFT REJECTION AND TO PREVENT OR CONTROL XENOGRAFT REJECTION | WILLIAMS JAMES W (US) | 1996-01-18 | — | — | WO | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| EP-0665013-A1 | Method of treating hyperproliferative vascular disease | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-08-02 | — | — | EP | claimed |
| WO-1995006640-A1 | CARBOCYCLIC AND HETEROCYCLIC FUSED-RING QUINOLINECARBOXYLIC ACIDS USEFUL AS IMMUNOSUPPRESSIVE AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-03-09 | — | — | WO | claimed |
| WO-1994024095-A1 | IMMUNOSUPPRESSIVE AGENTS | ABBOTT LABORATORIES (US) | 1994-10-27 | — | — | WO | claimed |
| EP-0617959-A1 | Pharmaceutical for the treatment of skin disorders | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-10-05 | — | — | EP | claimed |
| EP-0607775-A2 | Use of leflunomid for the inhibition of interleukin 1 beta | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-07-27 | — | — | EP | claimed |
| EP-0607776-A2 | Use of leflunomid for the inhibition of tumor necrosis factor alpha | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-07-27 | — | — | EP | claimed |
| EP-0607777-A2 | Use of leflunomid for the inhibition of interleukin 8 | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-07-27 | — | — | EP | claimed |
| EP-0607774-A2 | Use of leflunomid for the inhibition of interleukin 1 alpha | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-07-27 | — | — | EP | claimed |